ANTRIGE
LIVE

Serial Number

79189218

Owner

NOVARTIS AG

Filing Date

May 23, 2016

Add to watchlist:

No watchlists yet
View on USPTO

ANTRIGE Trademark

Serial Number: 79189218 • Registration: 5080145

ANTRIGE is a trademark filed by NOVARTIS AG on May 23, 2016. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

NOVARTIS AG (7,166 trademarks)

CH-4002
BASEL , CH

Entity Type: 03

Trademark Details

Filing Date

May 23, 2016

Registration Date

November 15, 2016

Published for Opposition

August 30, 2016

Cancellation Date

July 16, 2019

Goods & Services

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; anti-fungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculoskeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use; pharmaceutical products for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Feb 7, 2020 DENC
DEATH OF INTERNATIONAL REGISTRATION
Feb 7, 2020 DETH
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jun 9, 2017 OPNX
NOTIFICATION PROCESSED BY IB
Dec 30, 2016 GPNX
FINAL DISPOSITION NOTICE SENT TO IB
Dec 15, 2016 FICS
FINAL DISPOSITION PROCESSED
Dec 15, 2016 FIMP
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Dec 15, 2016 GPAR
REGISTERED-PRINCIPAL REGISTER
Nov 15, 2016 R.PR
PUBLISHED FOR OPPOSITION
Aug 30, 2016 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 10, 2016 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 10, 2016 OP2R
NOTICE OF PUBLICATION
Aug 10, 2016 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 28, 2016 CNSA
ASSIGNED TO EXAMINER
Jul 22, 2016 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 22, 2016 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 18, 2016 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jul 15, 2016 LIMI
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Jul 14, 2016 SDRC